What Zatoona Labs can help with
Questions we ran through Zatoona Labs on public data. Each one shows what we found, with the run's own figures and report.
Does human genetics support today's treatments for giant cell arteritis?
Today's drugs act on none of the 15 genes with genetic support. Only plasminogen has approved drugs, and they pull both ways.
Which sarcoma cell‑therapy targets are truly absent from healthy tissue?
Only MAGEA4 and PRAME are really confined to testis. NY-ESO-1 and SSX2 just look absent, and CD99 is everywhere.
Which compounds push psoriasis skin's gene changes back to normal?
PI3K and mTOR inhibitors lead. The 609 hits are about what any real signature reaches, so the ranking matters, not the count.
Did losartan for Marfan syndrome hold up in the clinic?
None of 8 registered trials stopped for lack of efficacy. Against no added drug, it slows aortic-root growth; against atenolol, it's no better.
How far can a published solubility equation be trusted on 80 molecules?
ESOL is typically about one log unit off on 74 measured molecules. Salts, a broken structure and seven drugs of unfamiliar chemistry get flagged.
What would a first Phase 3 protocol for nasal polyps look like?
A draft for expert review, built on 12 earlier trials. Its sample size runs from 38 to 200, by endpoint, effect size and power.
Your question here
Bring one well-scoped question and your data. We run it with you, in your environment.
Talk to usHave a research question like these?
Zatoona Labs is in early access. Tell us about your research question and we'll be in touch.